Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clarus’ Oral Testosterone’s Perceived Advantage Becomes Downfall At FDA Panel

This article was originally published in The Pink Sheet Daily

Executive Summary

Oral dosing is “double-edge sword” as unique concerns with Rextoro’s formulation leads to negative advisory committee vote for the testosterone replacement treatment despite panelists’ desire for an oral option.

You may also be interested in...



Keeping Track: Approvals For Mayzent, Mavenclad, Duaklir, Jatenzo And Cimzia

The latest drug development news and highlights from our US FDA Performance Tracker.

Surprise Approval For Clarus' Oral Testosterone Includes Black Box, No REMS

Jatenzo clears US FDA 15 months after second negative advisory committee review. 

US FDA Approval Climate: What Do The Oral Testosterone Reviews Tell Us?

Second go-round for oral testosterone could have marked new boundary on how far FDA is willing to go in approving new entrants to a market with widespread historic off-label use and CV risks.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS077675

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel